Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-02-08
2005-02-08
Kunz, Gary (Department: 1647)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C424S009100, C424S009200, C514S340000
Reexamination Certificate
active
06852496
ABSTRACT:
Analogs of FK506 that do not bind FKBP-12 have been found to effectively promote nerve cell growth and regeneration, thereby speeding functional recovery of damaged nervous tissue and axonal regeneration without causing immunosuppression.
REFERENCES:
patent: 3595955 (1971-07-01), De Boer et al.
patent: 3987035 (1976-10-01), Rinehart, Jr. et al.
patent: 4075339 (1978-02-01), Rinehart, Jr. et al.
patent: 4261989 (1981-04-01), Sasaki et al.
patent: 5192773 (1993-03-01), Armistead et al.
patent: 5330993 (1994-07-01), Armistead et al.
patent: 5387584 (1995-02-01), Schnur
patent: 5516797 (1996-05-01), Armistead et al.
patent: 5525523 (1996-06-01), Soldin
patent: 5543423 (1996-08-01), Zelle et al.
patent: 5612350 (1997-03-01), Or et al.
patent: 5614547 (1997-03-01), Hamilton et al.
patent: 5620971 (1997-04-01), Armistead et al.
patent: 5622970 (1997-04-01), Armistead et al.
patent: 5639592 (1997-06-01), Evans et al.
patent: 5665774 (1997-09-01), Armistead et al.
patent: 5717092 (1998-02-01), Armistead et al.
patent: 5780484 (1998-07-01), Zelle et al.
patent: 5786378 (1998-07-01), Hamilton et al.
patent: 5801197 (1998-09-01), Steiner et al.
patent: 5811434 (1998-09-01), Zelle et al.
patent: 5840736 (1998-11-01), Zelle et al.
patent: 5968921 (1999-10-01), Gold
patent: 6037370 (2000-03-01), Armistead
patent: WO 9204370 (1992-03-01), None
patent: WO 9219593 (1992-11-01), None
patent: WO 9219745 (1992-11-01), None
patent: WO 9221313 (1992-12-01), None
patent: WO 9307269 (1993-04-01), None
patent: WO 9314215 (1993-07-01), None
patent: WO 9323548 (1993-11-01), None
patent: WO 9640140 (1996-12-01), None
patent: WO 9640633 (1996-12-01), None
patent: WO 9641609 (1996-12-01), None
patent: WO 9718828 (1997-05-01), None
patent: WO 9820891 (1998-05-01), None
patent: WO 9820892 (1998-05-01), None
patent: WO 9820893 (1998-05-01), None
patent: WO 9921552 (1999-05-01), None
US 5,654,332, 8/1997, Armistead (withdrawn)*
Harding et al., Naturen 341:758-760, 1989.*
Siekierka et al., Nature 341:755-57, 1989.*
Segnitz and Gehring, The Function of Steroid Hormone Receptors is Inhibited by the hsp90-specific Compound Geldanamycin, The Journal of Biological Chemistry 272:18694-18701 (1997).
Smith et al., Progesterone Receptor Structure and Function Altered by Geldanamycin, an hsp90-Binding Agent, Molecular and Cellular Biology 15:6804-6812 (1995).
An et al., Depletion of p185erbB2, Raf-1 and Mutant p53 Proteins by Geldanamycin Derivatives Correlates with Antiproliferative Activity,Cancer Chemother. Pharmacol. 40:60-64 (1997).
Armistead et al., Design, Synthesis and Structure of Non-macrocyclic Inhibitors of FKBP12, the Major Binding Protein for the Immunosuppressant FK506,Acta CrystD51:522-528 (1995).
Czar et al., Geldanamycin, a Heat Shock Protein 90-Binding Benzoquinone Ansamycin, Inhibits Steroid-Dependent Translocation of the Glucocorticoid Receptor from the Cytoplasm to the Nucleus,Biochemistry36:7776-7785 (1997).
Gold et al., A Nonimmunosupressant FKBP-12 Ligand Increases Nerve Regeneration,Experimental Neurology147:269-278 (1997).
Grenert et al., The Amino-terminal Domain of Heat Shock Protein 90 (hsp90) That Binds Geldanamycin Is an ATP/ADP Switch Domain That Regulates hsp90 Conformation,The Journal of Biological Chemistry272:23843-23850 (1997).
Hamilton, G.S., and Steiner J.P., Neuroimmunophilin Ligands as Novel Therapeutics for the Treatment of Degenerative Disorders of the Nervous System,Current Pharmaceutical Design3:405-428 (1997).
Hamilton et al., FKBP12-Binding Domain Analogues of FK506 Are Potent, Nonimmunosupressive Neurotrophic Agents in Vitro and Promote Recovery in a Mouse Model of Parkinson's Disease,Bioorganic and Medical Chemistry Letters7:1785-1790 (1997).
Hartson et al., Modular Folding and Evidence for Phosphorylation-Induced Stabilization of an hsp90-dependent Kinase,The Journal of Biological Chemistry273:8475-8482 (1998).
Johnson, J.L., and Toft, D.O., Binding of p23 and hsp90 During Assembly with the Progesterone Receptor,Molecular Endocrinology9:670-678 (1995).
Lawson et al., Geldanamycin, an hsp90/GRP94-Binding Drug, Induces Increased Transcription of Endoplasmic Reticulum (ER) Chaperones via the ER Stress Pathway,Journal of Cellular Physiology174:170-178 (1998).
Owens-Grillo et al., The Cyclosporin A-binding Immunophilin CyP-40 and the FK506-binding Immunophilin hsp56 Bind to a Common Site on hsp90 and Exist in Independent Cytosolic Heterocomplexes with the Untransformed Glucocorticoid Receptor,The Journal of Biological Chemistry270:20479-20484 (1995).
Owens-Grillo et al., Binding of Immunophilins to the 90 kDa Heat Shock Protein (hsp90) via a Tetratricopeptide Repeat Domain Is a Conserved Protein Interaction in Plants,Biochemistry35:15249-15255 (1996).
Owens-Grillo et al., A Model of Protein Targeting Mediated by Immunophilins and Other Proteins That Bind to hsp90 via Tetratricopeptide Repeat Domains,The Journal of Biological Chemistry271:13468-13475 (1996).
Pratt, W.B., The Role of the hsp90-based Chaperone System in Signal-Transduction by Nuclear Receptors and Receptors Signaling Via MAP Kinase,Annu. Rev. Pharmacol. Toxicol. 37:297-326 (1997).
Pratt, W.B., The hsp90-based Chaperone System: Involvement in Signal Transduction from a Variety of Hormone and Growth Factor Receptors,Minireview: Department of Pharmacology, The University of Michigan Medical School, 420-434 (1998).
Pratt, W.B. and Toft, D.O., Steroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones,Endocrine Reviews18:306-360 (1997).
Radanyi et al., The Ability of the Immunophilin FKBP59-HBI to Interact with the 90-kDa Heat Shock Protein is Encoded by its Tetratricopeptide Repeat Domain,Proc. Natl. Acad. Sci. USA91:11197-11201 (1994).
Ratajczak, T. and Carrello, A. Cyclophilin 40 (CyP-40), Mapping of Its hsp90 Binding Domain and Evidence That FKBP52 Competes with CyP-40 for hsp90 Binding,The Journal of Biological Chemistry, 271:2961-2965 (1996).
Sanchez, E.R. and Ning, Y-M., Immunophilins, Heat Shock Proteins, and Glucocorticoid Receptor Actions in Vivo,Methods9:188-200 (1996).
Scheibel et al., Two Chaperone Sites in Hsp90 Differing in Substrate Specificity and ATP Dependence,Proc. Natl. Acad. Sci. USA95:1495-1499 (1998).
Schnur et al., erbB-2 Oncogene Inhibition by Geldanamycin Derivatives: Synthesis, Mechanism of Action, and Structure-Activity Relationships,J. Med. Chem. 38:3813-3820 (1995).
Schnur et al., Inhibition of the Oncogene Product P185erbB-2in Vitro and in Vivo by Geldanamycin and Dihydrogeldanamycin Derivatives,J. Med. Chem. 38:3806-3812 (1995).
Schulte et al., Disruption of the Raf-1-Hsp90 Molecular Complex Results in Destabilization of Raf-1 and Loss of Raf-1-Ras Association,The Journal of Biological Chemistry270:24585-24588 (1995).
Smith, D.F., Dynamics of Heat Shock Protein 90-Progesterone Receptor Binding and the Disactivation Loop Model for Steroid Receptor Complexes,Molecular Endocrinology7:1418-1429 (1993).
Stancato et al., The hsp90-binding Antibiotic Geldanamycin Decreases Raf Levels and Epidermal Growth Factor Signaling without Disrupting Formation of Signaling Complexes or Reducing the Specific Enzymatic Activity of Raf Kinase,The Journal of Biological Chemistry272:4013-4020 (1997).
Stebbins et al., Crystal Structure of an Hsp90-Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent,Cell89:239-250 (1997).
Steiner et al., Neurotrophic Immunophilin Ligands Stimulate Structural and Functional Recovery in Neurodegenerative Animal Models,Proc. Natl. Acad. Sci. USA94:2019-2024 (1997).
Steiner et al., Neurotrophic Actions of Nonimmunosupressive Analogues of Immunosupressive Drugs FK506, Rapamycin and Cyclosporin A,Nature Medicine3:421-428 (1997).
Tanzer L. and Jones K.J., Gonadal Steroid Regulation of Hamster Facial Nerve Regulation: Effects of Dihydrotestosterone and Estradiol,Experimental Neurology146:258-264 (1997).
Walsh et al., Cyclosporin A, the Cyclophilin Class of Peptidylprolyl Isomerases, and Blockade of T Cell Signal Transduction,The Journal of Biological Chemistry267:13115-13118 (1992).
Whitesell et al., Inhibition of Heat Shock Protein HSP
Klarquist & Sparkman, LLP
Kunz Gary
Oregon Health and Science University
Turner Sharon
LandOfFree
Methods of screening for agents that promote nerve cell growth does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of screening for agents that promote nerve cell growth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of screening for agents that promote nerve cell growth will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3461317